MS Briefs

Baseline Neurofilament Light Levels Track With Brain Volume Loss in MS


 

Key clinical point: Baseline levels of the neuropeptide neurofilament light (NfL) correlated with changes in brain volume at the 5- and 10-year marks in patients with multiple sclerosis.

Major finding: At 10 years, the correlation coefficient between baseline NfL and brain volume loss was –0.395 (P = 0.42).

Study details: Prospective cohort study that obtained baseline cerebrospinal fluid NfL levels and sequential brain MRIs in 44 patients with multiple sclerosis.

Disclosures: Dr. Bhan reported receiving research funding from Novartis Norway; two coauthors reported financial relationships with several pharmaceutical companies.

Citation: Bhan A et al. ECTRIMS 2019, Abstract P592 .

Recommended Reading

Plasma exchange in natalizumab-related PML shows no benefit, possible harm
ICYMI Multiple Sclerosis
Even with no disease activity, recurrence risk near 50% when stopping DMTs for MS
ICYMI Multiple Sclerosis
Continuation of natalizumab treatment reduces risk of MS relapses during pregnancy
ICYMI Multiple Sclerosis
Continuous Treatment Reduces Risk of Confirmed Disability Progression in MS
ICYMI Multiple Sclerosis
Newer Drugs Provide Superior Disease Activity Control in Pediatric MS
ICYMI Multiple Sclerosis
Even With No Disease Activity, Recurrence Risk Near 50% When Stopping DMTs for MS
ICYMI Multiple Sclerosis
Tocilizumab beat azathioprine for NMOSD
ICYMI Multiple Sclerosis
Baseline neurofilament light levels track with brain volume loss in MS
ICYMI Multiple Sclerosis
Intensive cognitive training may be needed for memory gains in MS
ICYMI Multiple Sclerosis
Investigators use ARMSS score to predict future MS-related disability
ICYMI Multiple Sclerosis